Show simple item record

dc.contributor.authorBermúdez López, Marcelino
dc.contributor.authorArroyo, David
dc.contributor.authorBetriu i Bars, M. Àngels
dc.contributor.authorMasana, Luis
dc.contributor.authorFernández i Giráldez, Elvira
dc.contributor.authorValdivielso Revilla, José Manuel
dc.date.accessioned2018-04-25T10:11:20Z
dc.date.available2018-08-27T22:20:15Z
dc.date.issued2017-08-27
dc.identifier.issn1472-8222
dc.identifier.urihttp://hdl.handle.net/10459.1/63143
dc.description.abstractAbstract INTRODUCTION: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
dc.description.sponsorshipThis work was supported by the intramural program of the IRBLleida, Instituto de Salud Carlos III (RETIC RD16/0009/0011, FIS PI16/01354) and FEDER funds.
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1080/14728222.2017.1369961
dc.relation.ispartofExpert Opinion on Therapeutic Targets, 2017, vol. 21, núm.10, p. 967-976
dc.rights(c) Taylor & Francis, 2017
dc.subjectAtherosclerosis
dc.subjectCardiovascular disease
dc.subjectChronic kidney disease
dc.subjectDyslipidemia
dc.subjectLipoproteins
dc.titleNew perspectives on CKD-induced dyslipidemia
dc.typeinfo:eu-repo/semantics/article
dc.date.updated2018-04-25T10:11:22Z
dc.identifier.idgrec026129
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.identifier.doihttps://doi.org/10.1080/14728222.2017.1369961


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record